Showing 4321-4330 of 10058 results for "".
- FDA Approves EBGLYSS 8-Week Dosings in Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-ebglyss-8-week-dosings-in-atopic-dermatitis/2487424/The US Food and Drug Administration (FDA) has approved an every-8-week maintenance dosing regimen for EBGLYSS® (lebrikizumab-lbkz) in adults and adolescents aged 12 years and older weighing at least 40 kg with moderate-to-severe atopic dermatitis, according to an
- Maternal Type 2 Diabetes Not Linked to Reduced AD Risk in Children: Studyhttps://practicaldermatology.com/news/maternal-type-2-diabetes-not-linked-to-reduced-ad-risk-in-children-study/2487400/New research suggests maternal type 2 diabetes mellitus (T2DM) does not independently influence the risk of atopic dermatitis (AD) in children. Researchers for a retrospective cohort study analyzed electronic medical and birth records from Clalit Health Services in Israel (n = 314,224 moth
- Review: GLP-1 Receptor Agonists May Benefit Both Psoriasis and Metabolic Diseasehttps://practicaldermatology.com/news/review-glp-1-receptor-agonists-may-benefit-both-psoriasis-and-metabolic-disease/2487389/Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may offer additional benefits for patients with psoriasis, according to a new review and primer from the National Psoriasis Foundation Medical Board. The authors noted GLP-1 RAs have been associated with reductions in Psoriasis Area and
- SCRATCH-AD: Rapid Itch Reduction, Biomarker Improvements with Ruxolitinibhttps://practicaldermatology.com/news/scratch-ad-rapid-itch-reduction-biomarker-improvements-with-ruxolitinib/2487381/Patients with atopic dermatitis (AD) treated with ruxolitinib 1.5% cream experienced rapid and sustained reductions in itch alongside improvements in disease-associated biomarkers, according to findings from the SCRATCH-AD study. The open-label SCRATCH-AD trial (NCT04839380) evaluated the
- Avapritinib Shows Dermatologic Benefits in Indolent Systemic Mastocytosishttps://practicaldermatology.com/news/avapritinib-shows-dermatologic-benefits-in-indolent-systemic-mastocytosis/2487380/Treatment with avapritinib led to substantial improvements in cutaneous disease manifestations among patients with indolent systemic mastocytosis (ISM), according to results from the phase 2 PIONEER study. Investigators for
- Study: Mineral Sunscreen Whitening Linked to Reduced Application and Protectionhttps://practicaldermatology.com/news/study-links-mineral-sunscreen-whitening-to-reduced-application-and-protection/2487379/New research published in the Journal of Drugs in Dermatology indicates mineral sunscreens produced visible whitening across all skin tones, with a pronounced effect in darker skin tones. Investigators evaluated 5 mi
- Study: AI Model Outperforms Early-Career Physicians in Skin Lesion Diagnosishttps://practicaldermatology.com/news/analysis-ai-model-outperforms-early-career-physicians-in-skin-lesion-diagnosis/2487332/Data from a new study show that a foundational AI model outperformed early career dermatologists in skin lesion diagnosis, but not more experienced dermatologists, when using a dataset designed to reflect real-world clinical scenarios.
- Genital Psoriasis Consensus Offers Age-Specific Roadmap for Clinical Carehttps://practicaldermatology.com/news/genital-psoriasis-consensus-offers-age-specific-roadmap-for-clinical-care/2487330/A new expert consensus manuscript in the American Journal of Clinical Dermatology offered recommendations aimed at improving the diagnosis and management of genital psoriasis, according to a press release from Arcutis. The publication represents the second manuscript, Arcutis said
- Skin Cancer Champions Announces Patient Advocacy Summithttps://practicaldermatology.com/news/skin-cancer-champions-announces-patient-advocacy-summit/2487322/The inaugural Patient Advocacy Summit, hosted by Skin Cancer Champions, will be held on October 30, 2026, at The Fairmont Copley Plaza in Boston, Massachusetts, the organization announced. “The Summit is an important milestone in our mission of providing support, advocacy, and amplifying t
- Analysis: Capecitabine Shows Clinical Activity in Advanced Head and Neck Cutaneous SCChttps://practicaldermatology.com/news/neoadjuvant-capecitabine-yields-42-complete-pathologic-response-rate-in-advanced-cscchn/2487303/Neoadjuvant capecitabine demonstrated encouraging clinical and pathologic responses in patients with advanced cutaneous squamous cell carcinoma of the head and neck (cSCCHN), according to findings from a prosp